How to Get Tresiba in Arizona

What Tresiba Is and Why Arizona Patients Request It

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, making once-daily dosing effective even when injection timing varies by several hours. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and extended approval to pediatric patients (age 1 and older) in 2019 [1]. Novo Nordisk markets two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL) in FlexTouch pens.

The DEVOTE cardiovascular outcomes trial (N=7,637) published in the New England Journal of Medicine in 2017 demonstrated that degludec was noninferior to insulin glargine U-100 for major adverse cardiovascular events, with a hazard ratio of 0.91 (95% CI 0.78 to 1.06) [2]. DEVOTE also showed a 40% relative reduction in severe hypoglycemia with degludec compared with glargine U-100 (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [2]. That hypoglycemia advantage is a primary reason Arizona endocrinologists and telehealth providers consider a switch from glargine or detemir.

Arizona's diabetes burden is significant context. The CDC reports that 11.3% of Arizona adults had diagnosed diabetes as of 2021, above the national median, and an additional 38.0% of U.S. adults met criteria for prediabetes in that same surveillance period [3]. Demand for optimized basal insulin regimens has grown alongside expanded telehealth access in the state.

Arizona Telehealth Law and Tresiba Prescribing

Telehealth providers licensed in Arizona may prescribe Tresiba after a valid patient-provider relationship is established. Arizona Revised Statutes Section 36-3601 through 36-3606 govern telemedicine practice; the state does not require an in-person visit before a telehealth prescription is issued for most chronic conditions, including diabetes [4]. A synchronous audio-video visit satisfies the standard of care for basal insulin initiation in most clinical scenarios.

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "Telehealth visits can be used effectively for diabetes management, including insulin initiation and titration, when the provider obtains a thorough history and the patient has access to glucose monitoring data" [5]. That guidance applies directly to degludec prescribing via telehealth in Arizona.

Prescribers who hold an Arizona DEA registration and an active Arizona medical, nursing, or physician assistant license may issue the prescription. Nurse practitioners and physician assistants with full prescriptive authority under Arizona law can prescribe insulin degludec without physician co-signature, provided they hold the appropriate collaborative practice documentation or independent licensure [4].

Typical telehealth workflow for a new Tresiba patient in Arizona runs as follows. The patient completes an intake form and uploads recent labs. The provider conducts a 20-to-30-minute video visit, reviews glucose logs, and issues an electronic prescription to the patient's chosen Arizona pharmacy. Same-day electronic transmission is standard. The patient typically receives the medication within one to three business days from a retail pharmacy, or three to seven business days if using a mail-order pharmacy.

Lab Requirements Before Tresiba Is Prescribed in Arizona

Most prescribers require a current HbA1c, fasting plasma glucose, and a basic or comprehensive metabolic panel before initiating insulin degludec. Results from within the past 90 days are generally acceptable; some telehealth platforms accept 180-day-old labs for established diabetic patients already using basal insulin.

The American Association of Clinical Endocrinology (AACE) 2022 Consensus Statement on insulin therapy recommends baseline HbA1c to set the titration target, renal function (serum creatinine and eGFR) to assess clearance considerations, and a lipid panel to characterize overall metabolic risk [6]. Degludec itself does not require dose adjustment for renal impairment according to the FDA prescribing label, but renal function influences the broader diabetes management plan [1].

A complete blood count is requested less universally but is standard at HealthRX before any new injectable diabetes therapy. Thyroid-stimulating hormone is added when the clinical history suggests thyroid disease, given the bidirectional relationship between thyroid status and glycemic control [7].

Patients already stable on another basal insulin who are transferring care to an Arizona provider often present with recent lab work. A telehealth provider may proceed with the visit using those results and schedule a follow-up HbA1c at three months post-transition.

The HealthRX Arizona Tresiba Intake Framework consolidates the minimum lab panel into three tiers. Tier 1 (required before prescribing): HbA1c, fasting glucose, eGFR/creatinine. Tier 2 (required within 30 days of first fill): lipid panel, CBC, urine albumin-to-creatinine ratio. Tier 3 (annual): TSH, vitamin B12 (for patients on metformin), hepatic function panel. This tiered approach allows same-visit prescribing when Tier 1 results are already on file, reducing time-to-medication without compromising clinical oversight.

How to Get a Tresiba Prescription in Arizona: Step-by-Step

Step 1. Choose a prescriber. Options include an in-person endocrinologist or primary care physician, or a telehealth platform licensed in Arizona. Telehealth reduces travel burden for patients in rural counties such as Navajo, Apache, and Greenlee, where endocrinology access is limited [3].

Step 2. Prepare your documentation. Gather current glucose logs (continuous glucose monitor data or fingerstick logs for the past 14 days), your current diabetes medication list, insurance card, and any prior authorization correspondence from your insurer.

Step 3. Complete the visit. The provider reviews your glucose pattern, determines the appropriate starting dose, and discusses injection technique. For type 2 patients new to basal insulin, the FDA label recommends 10 units subcutaneously once daily, titrated by 2 units every three days to a fasting glucose target [1]. For type 1 patients converting from another basal insulin, the dose is typically unit-for-unit.

Step 4. Pharmacy selection. The provider sends the prescription electronically. Major Arizona retail chains (CVS, Walgreens, Fry's/Kroger, Walmart, Safeway) stock or can order Tresiba U-100 and U-200. Walmart pharmacies in Arizona carry ReliOn insulin products but do not stock degludec; a separate order is needed. Mail-order pharmacies such as Express Scripts and CVS Caremark fill Tresiba for patients with compatible PBM contracts.

Step 5. Insurance and cost. If prior authorization is required, the prescriber submits clinical documentation (see the Prior Authorization section below). Without insurance, Tresiba U-100 FlexTouch (5-pen box) retails between $380 and $450 at Arizona pharmacies as of mid-2025. The Novo Nordisk savings program may reduce out-of-pocket cost for commercially insured patients; patients without insurance may qualify for the Novo Nordisk Patient Assistance Program, which provides Tresiba at no cost [8].

Prior Authorization for Tresiba in Arizona

Prior authorization is required by most Arizona commercial health plans and by most Medicare Part D plans that include Tresiba on their formulary. Arizona Medicaid (AHCCCS) does not cover Tresiba on its preferred drug list as of 2025, so prior authorization is not available through AHCCCS; patients must use an alternative payer or access assistance programs.

For commercial plans, prior authorization typically requires documentation of: (1) a confirmed diagnosis of type 1 or type 2 diabetes with ICD-10 codes E10.x or E11.x; (2) HbA1c above the plan's threshold (commonly 7.5% or 8.0% depending on the plan); (3) a trial of at least one formulary-preferred basal insulin (most commonly insulin glargine U-100, biosimilar glargine, or NPH) with documented inadequate glycemic control or recurrent hypoglycemia; and (4) prescriber attestation that Tresiba is medically necessary [9].

The DEVOTE trial data provide strong clinical justification for the hypoglycemia step-through criterion: a 40% reduction in severe hypoglycemia rate (rate ratio 0.60, P<0.001) is a quantifiable outcome that plan medical directors routinely accept [2]. Some Arizona plans also accept documentation of nocturnal hypoglycemia events from CGM downloads as supporting evidence.

Arizona law (A.R.S. Section 20-3151 et seq.) requires insurers to provide a prior authorization decision within three business days of receiving a complete request, or within one business day for urgent requests [4]. In practice, telehealth platforms that use integrated electronic prior authorization tools often receive decisions within 24 to 48 hours. Expedited appeals are available if a PA is denied and the prescriber certifies medical urgency.

Arizona Pharmacy Access: Retail, Mail-Order, and 503A Compounding

Retail pharmacies. Arizona has more than 1,200 licensed retail pharmacy locations. Tresiba U-100 and U-200 FlexTouch pens are stocked or readily orderable at most chain pharmacies. Patients in Maricopa and Pima counties have same-day access in most cases. Rural patients may face a one-to-three-day ordering delay.

Mail-order pharmacies. Ninety-day supplies through mail-order reduce per-unit cost when covered by insurance. Express Scripts, CVS Caremark, and Optum Rx each have Arizona-licensed dispensing agreements. Shipping time from order to arrival averages three to five business days for standard shipping within Arizona [10].

503A compounding pharmacies. Arizona-licensed 503A pharmacies may compound insulin degludec for individual patients when a valid prescription from a licensed prescriber exists. The FDA regulates 503A pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act; they compound for specific patients rather than producing drug in advance at scale [11]. The compound must be prepared from FDA-approved bulk active pharmaceutical ingredient. Compounded degludec is not bioequivalent-tested against the brand product; prescribers and patients should be aware of this distinction. Cost through a 503A pharmacy may be lower than brand Tresiba without insurance, but clinical validation of the compounded product is the patient's and prescriber's shared responsibility.

Biosimilar options. As of mid-2025, no FDA-approved biosimilar to insulin degludec has launched in the United States. The FDA has approved biosimilar insulin products for glargine (Semglee, Rezvoglar) and lispro (Admelog), but degludec biosimilars remain in development. Arizona formularies that require a glargine trial first may accept a documented glargine failure before approving brand Tresiba [12].

Transferring an Existing Tresiba Prescription to Arizona

Patients relocating to Arizona or establishing care with a new Arizona provider can transfer a Tresiba prescription under specific conditions. A retail pharmacy transfer is straightforward: any Arizona pharmacy can contact the out-of-state pharmacy to transfer a prescription if Arizona law allows refills remaining on the script. Federal law permits transfer of non-controlled substances between pharmacies across state lines.

For telehealth transfers, the new Arizona-licensed provider must conduct a fresh clinical evaluation before issuing a new prescription, even if the patient has been stable on Tresiba for years. The prescriber may review prior records, CGM data, and the existing prescription as supporting documentation, but the new prescription must originate from the Arizona provider's own clinical judgment. This protects the provider's DEA registration and satisfies the Arizona Board of Medical Examiners' prescribing standards [4].

Patients should bring the following to a transfer visit: the current Tresiba pen or vial (to confirm concentration), the prescribing physician's contact information, the most recent HbA1c result, and any prior authorization approval letters from the previous insurer. If switching insurers in Arizona, a new prior authorization may be required even if the prior insurer approved Tresiba.

Dosing, Titration, and Monitoring After Starting Tresiba in Arizona

The FDA-approved starting dose for type 2 diabetes patients naive to basal insulin is 10 units subcutaneously once daily. Titration proceeds in 2-unit increments every three days, targeting a fasting glucose of 80 to 130 mg/dL per ADA 2024 Standards (individualized to patient) [5]. The FDA label for type 1 patients recommends calculating approximately one-third to one-half of the total daily insulin dose as basal, with the remainder as rapid-acting insulin [1].

A key pharmacokinetic advantage of degludec is dose-timing flexibility. The SWITCH 1 trial (N=501, type 1 diabetes) showed that forced variability in injection timing of up to 8 to 9 hours did not worsen glycemic control or hypoglycemia rates compared with fixed once-daily dosing [13]. This flexibility is clinically meaningful for shift workers and patients with irregular schedules, a population present throughout Arizona's manufacturing and agriculture sectors.

The ADA recommends HbA1c measurement every three months during the titration phase, then every six months once stable [5]. Fasting glucose self-monitoring at least three days per week helps guide titration between clinic visits. Continuous glucose monitoring (CGM) is preferred when accessible; Arizona Medicaid covers CGM for insulin-requiring patients under specific AHCCCS criteria, even though Tresiba itself is not on the AHCCCS formulary.

Hypoglycemia management education must accompany any new basal insulin prescription. The Endocrine Society's 2022 Clinical Practice Guideline on diabetes in older adults recommends a less stringent HbA1c target (7.5 to 8.5%) and particular attention to hypoglycemia risk for patients over age 65 [14]. Arizona's population includes a large retirement community; prescribers should individualize targets accordingly.

Cost Reduction Strategies for Arizona Patients

Tresiba without insurance costs approximately $380 to $450 per box of five FlexTouch pens (U-100, 300 units per pen) at Arizona retail pharmacies as of mid-2025. Several cost-reduction pathways exist.

The Novo Nordisk Patient Assistance Program provides Tresiba at no cost to patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level without prescription drug coverage) [8]. Applications are submitted by the prescriber's office and typically processed within two to four weeks.

The Novo Nordisk savings card for commercially insured patients may reduce monthly cost to $99 or less. Patients pay this co-pay rate regardless of plan tier, provided they are not enrolled in a federal health program (Medicare, Medicaid, TRICARE) [8].

GoodRx and similar discount platforms list degludec prices at Arizona pharmacies. GoodRx prices for a five-pen box ranged from $340 to $420 at Arizona CVS and Walgreens locations in June 2025, depending on the specific GoodRx coupon applied. These discounts cannot be combined with insurance.

Mark Cuban's Cost Plus Drugs does not list insulin degludec as of mid-2025. Patients seeking the lowest possible cash price should compare GoodRx, RxSaver, and direct manufacturer assistance before filling.

Injection Technique and Storage in Arizona's Climate

Arizona's summer temperatures regularly exceed 110 degrees Fahrenheit in the Phoenix metro area and the Sonoran Desert. Insulin degludec is stable at room temperature (up to 86 degrees Fahrenheit, or 30 degrees Celsius) for up to 56 days after first use, per the FDA-approved labeling [1]. Unopened Tresiba pens must be refrigerated at 36 to 46 degrees Fahrenheit until first use.

Patients leaving insulin in a parked car or direct sunlight during an Arizona summer will degrade the product rapidly. The FDA label notes that insulin exposed to temperatures above 86 degrees Fahrenheit should be discarded [1]. Insulated travel pouches rated for temperatures up to 104 degrees Fahrenheit (such as the FRIO evaporative cooling wallet) are appropriate for outdoor activities; patients should verify the pouch's rated upper temperature before relying on it in extreme Arizona heat.

Injection sites should rotate among abdomen, thigh, and upper arm. No site is contraindicated specifically for degludec, but lipohypertrophy from repeated injections at the same site reduces absorption reliability. The American Diabetes Association recommends systematic rotation with at least 1 cm between injection sites [5].

Monitoring for Long-Term Safety

The DEVOTE trial followed 7,637 patients with type 2 diabetes and high cardiovascular risk for a median of 2 years [2]. Cardiovascular outcomes (nonfatal MI, nonfatal stroke, cardiovascular death) occurred at a rate of 8.5% with degludec versus 9.3% with glargine, confirming noninferiority [2]. No new safety signals emerged for retinopathy, nephropathy, or malignancy.

Weight gain is common with basal insulin initiation. DEVOTE participants gained a mean of 1.0 kg with degludec versus 0.5 kg with glargine over 2 years [2]. Prescribers should discuss this with patients and, where appropriate, consider concurrent GLP-1 receptor agonist therapy, which may offset insulin-associated weight gain [15].

Injection-site reactions occur in fewer than 2% of patients per the FDA label [1]. Systemic allergic reactions are rare. Lipodystrophy is a long-term risk with any insulin and is mitigated by rotation.